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ABSTRACT
Introduction: Thymoquinone (TQ), a bioactive compound from Nigella sativa is known for its various medicinal 
properties. Due to the low solubility of TQ, nanostructured lipid carrier (NLC) has been used as a delivery system 
to improve its efficacy. Nevertheless, the effect of TQ-NLC when administered intravenously is unclear. This study 
investigated the acute toxicity profile of intravenous administration of TQ-NLC in an in vivo model. Methods: Twelve 
female Sprague dawley rats were assigned randomly into two groups (n=6); a control and a treatment group that 
received normal saline and 25 mg/kg TQ-NLC, respectively, via intravenous injection. The rats were observed for 14 
days for any alterations to their  usual physical conditions such as behaviour and mortality, body weight, food intake, 
organ-to-body weight ratio, and haematological, biochemical and histopathological profile. Results: There were no 
significant changes (p>0.05) in the body weight, food intake, organ-to-body weight ratio, and haematological, bio-
chemical and histopathological profile between TQ-NLC treatment and the control group. However, inflammation 
was observed at the site of injection on the rat’s tail. Conclusion: Intravenous administration of TQ-NLC (25 mg/kg) 
did not exert acute toxic effect in female Sprague dawley rats. The data can be used as a basis to further develop TQ-
NLC as a potential therapeutic drug. 
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INTRODUCTION
Nigella sativa (N. sativa) (Linn.) of the Ranunculaceae 
family is a medicinal plant commonly known as black 
cumin. The seeds of this plant and its oil are widely used 
as home remedy to treat various ailments in regions 
like the Middle East, India, Bangladesh, Pakistan, 
Mediterranean and also Europe for centuries. Asthma, 
inflammation, cough, bronchitis, diabetes, fever, 
dizziness, eczema, influenza and hypertension are 
among the diseases treated with black cumin seeds (1). 
A key bioactive component of N. sativa seed volatile oil 
is 2-isopropyl-5-methyl-benzoquinone, thymoquinone 
(TQ) (2). 
TQ has been widely reported for its vast pharmacological 
effects in various disease models both in vitro and in vivo. 
TQ has potent anticancer properties in glioblastoma 
cells (3), lung cancer cells (4), neuroblastoma cells (5) 
and myeloblastic leukemia (6). Its anti-inflammatory (7), 
hepatoprotective (8), antioxidant and antihistaminic (9) 
activities has also been documented. 
TQ has limited bioavailability and solubility due to 
its hydrophobic properties that eventually decreases 
its effectiveness in clinical use (10). Application of 
nanotechnology is an alternative to overcome this 
problem. Nanocarriers have been used to help the drug 
to be more soluble in aqueous solution, increasing 
their bioavailability, and enhancing the drug’s half-
life in serum (11). Nanoparticle delivery system is 
usually carried out when an intended drug is dissolved, 
entrapped, absorbed, attached and/or encapsulated 
onto or into nano-matrix (12). Lipid nanoparticles have 
been identified to provide several advantages due to its 
bioacceptable and biodegradable nature, leading it to 
have lower toxicity compared to other nanocarriers (13). 
TQ has been encapsulated with nanostructured lipid 
carrier (NLC), herein referred as TQ-NLC, which 
increased its efficacy and solubility, making injection 
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of this compound possible (14). Lipid carrier is a drug 
vehicle that helps in improving the solubility of active 
compounds and controlling drug release (12). TQ-NLC 
exhibited anti-proliferative activity towards cervical 
cancer cell lines (HeLa and SiHa) and breast cancer cell 
lines (MCF-7 and MDA-MB-231) (14). In order to further 
establish TQ-NLC as a potential drug, toxicological 
evaluation is essential to determine the highest exposure 
of a particular drug that shows no toxicity resulting in 
the expected efficacy (15).
We have recently reported on the acute and subacute 
toxicity profiles of oral administration of TQ-NLC (16). 
Nevertheless, the effect of TQ-NLC when administered 
intravenously remains unclear. Toxicological profile 
upon intravenous injection is important as the drug will 
directly go into the blood system for systemic action 
(12) bypassing the first-pass metabolism and absorption 
phase. The effect of intravenous administration is 
different to oral administration as the drug is vulnerable 
to the rigorous activity of digestive juices and has to 
bypass the physiological barriers in the gastric and 
intestinal environment that includes the mucosal barrier, 
enterocytes of the intestinal epithelium, tight junctions 
between epithelial cells and subepithelial tissues (17). 
Intravenous route of administration is a more reliable 
route as it is quicker and efficient in exhibiting immediate 
therapeutic effects because the drugs could also directly 
reach target organs. Drugs that have short half-life or 
duration of action is more suitable to be given via this 
route as it could be delivered in a more uniform rate, 
thus reaching a bioavailability of 100%. Furthermore, 
intravenous drug administration is a better option for 
patients who are uncooperative as they are unconscious 
or likely to vomit due to the unpleasant taste of the oral 
drugs. This study investigated the acute toxicity profile 
of intravenous administration of TQ-NLC in Sprague 
dawley rats.
 
MATERIALS AND METHODS
Synthesis of TQ-NLC
TQ-NLC was synthesised according to the protocol 
outlined by Ng et al. (14) by a high-pressure 
homogenisation process. First, two matrices consisting 
the lipid and aqueous matrix were prepared. The lipid 
matrix was prepared by mixing hydrogen palm oil, 
lecithin and olive oil and melted at 70°C. Aqueous 
matrix was prepared by mixing sorbitol, polysorbate 80 
and thimerosal in deionised water and heated at 70°C. 
Next, TQ was added to the lipid matrix before dispersion 
with aqueous matrix. Subsequently, the pre-emulsion 
was obtained by high-speed stirring by Ultra-Turrax 
(IKA-werke, GmBH, Germany) for 10 minutes at 13 
000 rpm at 70°C. The pre-emulsion was homogenised 
at 1000 bars for 20 cycles by using a high-speed 
homogeniser EmulsiFlex-C50 (Avestin, Mannheim, 
Germany). Immediately, the emulsion obtained was let 
to crystallise at room temperature to form TQ-NLC (18).
Animal
Female Sprague dawley rats with initial body weight 
ranging from 180 to 220 g and eight weeks of age were 
used in this experiment. Prior to any procedures, the rats 
were acclimatised for a minimum of one week. Animals 
were housed two in a cage under room temperature of 
29-32°C and humidity of 70-80% with 12 hours light-
dark cycles. The rats had access to standard chow 
(Specialty Feeds, Glen Forrest, WA, Australia) and tap 
water ad libitum. The experiments conformed to ethical 
guidelines and were carried out with the approval of 
Institutional Animal Care and Use Committee (IACUC) 
of Universiti Putra Malaysia (Reference number: UPM/
IACUC/AUP-R074/2015). 
Experimental Design
TQ-NLC at a dose of 25 mg/kg of was administered via 
intravenous (i.v) injection into the rat’s tail, after 8 hours 
of fasting. Then, at an interval of 48 hours, the same 
dose was employed to four other rats. In parallel, five 
rats were administered with normal saline as control 
group. The animals were observed closely during the 
first 24 hours and once daily for 14 days (19).
Hippocratic screening (20) was carried out on the rats 
where the analysed parameters include: 
i) conscious state (general activity)
ii) activity and coordination of motor system and muscle 
toning (response to tail touch and grip, straightening and 
strength to grab)
iii) reflexes (corneal and headset)
iv) activities on the central nervous system (tremors, 
convulsions, straub, sedation, anaesthesia and ataxia)
v) activities on the autonomic nervous system (lacrimation, 
cyanosis, ptosis, salivation and piloerection)
All rats’ feed and water consumption, and body weights 
were recorded on a daily basis (19). 
On day 14, all the rats were fasted for one day before 
they were anaesthetised with ketamine (25 mg/kg; ip) 
and xylazine (10 mg/kg; ip). Approximately 1 mL of 
fresh blood was allocated for haematological analysis. 
The remaining blood were placed into plain tubes and 
centrifuged at 12 000 rpm (Hettich EBA21, Germany) 
for 10 minutes to obtain serum for biochemical analysis. 
The liver, spleen, lung, heart, and kidneys were 
dissected out and weighed. The organs were placed 
onto square grid lines for observation of changes in 
the gross morphology. Each rat’s organ weight-to body 
weight ratio was calculated. The organs were placed in 
10% formalin fixative.
Hematological and Biochemical Analysis
Haematological parameters that include red blood 
cell (RBC), haemoglobin concentration, haematocrit 
(packed cell volume, PCV), mean corpuscular volume 
(MCV), white blood cells (WBC) and platelet counts 
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(thrombocytes) were analysed using an automated 
hematology analyser (Sysmex-XT-1800, Norderstedt, 
Germany). 
A chemical analyser (Selectra-XL, Huizen, Netherlands) 
was used to perform the biochemical analysis. The 
hepatic function was determined by the level of serum 
alkaline phosphatase (ALP), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), total protein, 
albumin and total bilirubin. The renal function was 
evaluated based on the level of blood urea nitrogen and 
serum creatinine.
Histopathological Analysis
The organs that were fixed in 10% formalin for least 
24 hours were processed (Leica TP 1020; Leica 
Biosystems Nussloch GmbH, Buffalo Grove, IL, USA) 
and embedded in paraffin wax. Tissues were sectioned 
at 5 µm thickness, mounted onto glass slides and stained 
with haematoxylin and eosin. Finally, a total of 10 fields 
from each slide were observed at 40X magnification 
under a light microscope (Leica, Wetzlar, Germany) for 
any histological changes. 
Statistical Analysis
All data are expressed as mean ± standard error of mean 
(S.E.M.) values. GraphPad Prism version 5 was used for 
statistical evaluation of the data. Statistical significance 
was determined by two way Analysis of Variance 
(ANOVA) followed by Bonferroni post hoc analysis for 
behaviour and histopathological study. Hematological 
and biochemical test were analysed using Mann-
Whitney test.  p value less than ≤0.05 was considered 
statistically significant. 
 
RESULTS
Table 1 shows the body weight of rats throughout the 
experimental period. There were no significant changes 
(p>0.05) in the body weight of rats in both control and 
25 mg/kg; i.v TQ-NLC treated groups.
Table I: Body weight of control and rats treated with 25 mg/kg of TQ-
NLC
Day Control (g) 25 mg/kg TQ-NLC (g)
1 182. 60 ± 21.76 238.20 ± 14.92
4 180.00 ± 21.75 230.80 ± 14.86
7 192.20 ± 30.68 229.00 ± 17.16
11 193.40 ± 29.17 236.20 ± 14.65
14 191.40 ± 28.47 235.40 ± 12.88
Results are shown as mean values ± S.E.M.; n=6 animals per group
Figure 1: Effect of intravenous administration of TQ-NLC on the food 
intake of rats. Data are presented as mean ± S.E.M.; n=6 animals per 
group.
Figure 1 shows that there was no significant difference 
(p>0.05) in the food intake between the control and 25 
mg/kg; i.v TQ-NLC treated groups.
Figure 2 represents the organ-to-body weight ratio 
between the two groups with no significant differences 
(p>0.05) in the weight of liver, spleen, lungs, heart and 
kidneys.
Figure 2: Effect of intravenous administration of 25 mg/kg TQ-NLC on 
the organ-to-body weight ratio of rats. Data are presented as mean ± 
S.E.M.; n=6 animals per group.
Figure 3 shows the haematological profile of rats in 
25 mg/kg; i.v TQ-NLC treated rats as compared to the 
control animals. There were no significant differences 
(p>0.05) in the RBC, Hb, PCV, MCV, WBC and 
thrombocytes counts. 
Figure 3: Effect of intravenous administration of TQ-NLC on the hae-
matological profile of rats. Data are presented as mean ± S.E.M.; 
n=6 animals per group. RBC= red blood cell, Hb= haemoglobin, 
PCV=packed cell volume haematocrit, MCV=mean corpuscular vol-
ume, WBC=white blood cell, Thro.= thrombocytes.
Figure 4 represents the effect of 25 mg/kg; i.v TQ-NLC on 
the biochemical profile of rats compared to the control 
group. There were no significant differences (p>0.05) 
in the serum ALP, ALT, creatinine, urea, total protein, 
albumin and total bilirubin levels. However, AST level 
was significantly (p<0.05) reduced in 25 mg/kg; i.v TQ-
NLC treated rats compared to control rats. 
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Figure 4: Effect of intravenous administration of TQ-NLC on the bi-
ochemical profile of rats. Data are presented as mean ± S.E.M.; n=6 
animals per group. *significantly different than control at (p ≤ 0.05). 
ALP= alkaline phosphate, AST=aspartate aminotransferase, ALT= se-
rum alanine aminotransferase, Creat.= creatinine, Tot. Prot.= total pro-
tein, Tot. Bil.= total bilirubin.  
Histological changes in the spleen tissue 14 days after 
saline and 25 mg/kg; i.v TQ-NLC are shown in Figure 
5. The spleen tissues of control rats exhibited normal 
morphology but the one of 25 mg/kg; i.v TQ-NLC treated 
rats showed formation of brown spots.
Signs of inflammation at the site of injection at the tail of 
rats were only noted in the group injected with 25 mg/
kg; i.v TQ-NLC as shown in Figure 6. 
DISCUSSION
Any form of formulation or substance that is established 
as drug needs to undergo a few screening tests. This is 
essential for the identification of the benefits and more 
Figure 5: Histology of the spleen after treat-
ment with TQ-NLC. Both groups show nor-
mal spleen condition (A and C) (10X magni-
fication). The spleen of the control group has 
normal white pulp (upper region) and red 
pulp (lower region) (B). Formation of brown 
spots (hemosiderin) (arrows) is observed in 
the rats treated with 25 mg/kg TQ-NLC (D) 
(40X magnification).
Figure 6: Inflammation at the site of injection on the tail 
if rats following 25 mg/kg; i.v TQ-NLC from day 1 to day 
14 (A-N). 
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importantly the possible adverse effects that the sub-
stance may exhibit. In this study, we carried out the 
acute toxicity of intravenously administered TQ-NLC to 
the overall health, major body organs and blood profile.
 No mortality was recorded throughout the 14 days of 
the study period indicating that TQ-NLC at 25 mg/kg 
was not lethal. Since none of the animals experienced 
body weight fluctuation of more than 10% from the ini-
tial one, it is believed that there was no adverse reaction 
to the general wellbeing of the rats. The adverse effects 
of drugs and chemicals can be determined by the chang-
es in body weight (21). Furthermore, TQ-NLC treated 
rats showed no difference in food intake indicating that 
the ability to access food and appetite were not affect-
ed by the treatment. Adverse reaction of the treatment 
could cause stress to the animals influencing their eating 
habits (22). Oral administration of TQ-NLC at a dose of 
50 mg/kg also showed no mortality but had 33% mortal-
ity rate at a high dose of 300 mg/kg (16).
There was also no apparent organ-to-body weight dif-
ference between treatment group and control group 
indicating that TQ-NLC did not cause toxicity to the 
body organs. In toxicological studies, analysis of organ-
to-body weight is a vital endpoint to identify potential 
harmful effects of chemicals (23). Furthermore it serves 
as a good indicator of any changes that has been trig-
gered chemically to the organs.
The blood profile readings fell within the normal range 
after treatment with 25 mg/kg, i.v TQ-NLC. Many tox-
icants cause toxicity to the hematopoietic system as it 
is one of the most sensitive targets for toxic chemicals. 
Therefore, the screening of chemicals for hematoxic-
ity could highly predict possible risk by the chemical 
or drug to be tested (24). Moreover, in this experiment, 
the substance was administered directly into the blood 
system. We, therefore, conclude that TQ-NLC has no 
untoward effects to the blood system. 
The readings for all biochemical parameters for kidney 
function inclusive of creatinine, urea, albumin levels and 
for liver function that includes ALT, ALP, total protein 
and total bilirubin of rats treated with 25 mg/kg; i.v TQ-
NLC were also in the normal range. Lower level of AST 
in the 25 mg/kg; i.v TQ-NLC group might be reflecting 
the inflammatory activity in the liver (25) due to the skin 
inflammation at the site of injection. Histological sec-
tions of kidneys and liver in the treated groups showed 
no abnormality or alterations to the normal structures 
suggesting that TQ-NLC showed no any undesired effect 
to the structure and function of kidneys and liver. Toxic 
substances, especially heavy metals could bioaccumu-
late in vital organs that causes damages and eventually 
death. Furthermore, the main site for the metabolism 
and production of various essential compounds. It also 
plays a role in the detoxification of toxic materials mak-
ing it an ideal organ to assess the toxic influence of a 
drug (26).
Our outcome is consistent when compared with the 
study by Ong et al. (16) where TQ-NLC was adminis-
tered orally. Biochemical and haematological parame-
ters indicated no signs of toxicity up to a dose of 100 
mg/kg. However, following of long term TQ-NLC con-
sumption, histological evaluations indicated possible 
liver toxicity but the organ’s functions are preserved. As 
mentioned earlier the drugs administered orally has to 
bypass the gastrointestinal barrier to get into the blood 
system but drugs employed intravenously is directly 
present into the blood stream making the bioavailability 
and drug effect to be exerted differently. 
The spleen of rats treated with 25 mg/kg, i.v TQ-NLC 
showed formation of brown spots or hemosiderin. He-
mosiderin is a by-product of ferritin which is produced 
from haemoglobin during hemolysis (27). This condition 
might be due to the inflammation that occurred in the 
rat’s tail following intravenous injection. It is possible 
that the degenerated red blood cells at the site of inflam-
mation are circulated in the blood. Upon reaching the 
spleen, the degenerated red blood cells are destroyed 
(28) as the macrophages in the white pulp of the spleen 
engulf them. Heme release iron which can be stored 
as ferritin inside the cells. Subsequently, in cytoplasm, 
ferritin is oxidised and degraded to form hemosiderin 
which is observed as brown spots in the spleen (27).
Inflammation occurred at the rat’s tails is postulated to 
be caused by the use of Polysorbate 80 in the formula-
tion of TQ-NLC. Polysorbate 80 was used to synthesis 
TQ-NLC to improve particle stability (14). Furthermore, 
previous studies have reported on similar incidence 
of skin inflammation at the site of injection where the 
substance was administered (29). Further optimization 
of this formulation should highly consider a substitute 
for Polysorbate 80 to prevent unwanted consequences 
when TQ-NLC is developed into a drug for human use.
CONCLUSION
In conclusion, intravenous administration of 25 mg/kg 
TQ-NLC did not exhibit acute toxicity in female Sprague 
dawley rats. However, TQ-NLC caused inflammation at 
the injection site. The data can be used as a basis to 
further develop TQ-NLC as a potential therapeutic drug.
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